DMPK, Dosage, Bioavailability
7:00 am Registration Opens & Coffee
Lost in Translation: Overcoming the Barriers of in-vitro & in-vivo Action of Cannabinoid- Derived Drugs to Improve Efficacy
8:00 am Meaningful in vitro Data on Cannabinoids: Providing Value to Clinical Study Design
Synopsis
- What is physiological and what’s not in cannabinoid research?
- Discussing the gap between a therapeutic dose and a toxic dose in-vitro
- Understanding the value of standardizing tissue culture assays for cannabinoids
8:30 am Designing Animal Models for Assessing Safety, Tolerability & Efficacy of Cannabinoids in Neurological Diseases
Synopsis
- Exploring appropriate animal models for drug testing
- Testing of efficacy in animal models in neurological disease areas
- Understanding the translational impact of animal model testing
9:00 am Rethinking the Approach to Advancing Cannabinoid-Based Drug Development: A Case Study of Musculoskeletal Pain & Inflammation
Synopsis
- Optimizing cannabinoid-based formulations for topical application
- Challenges with current preclinical models and their translation to human experience
- Using AI and observational data to determine the preclinical pathway
9:30 am Speed Networking
Synopsis
This session is the ideal opportunity to take advantage of face-to-face networking time and understand who is also prioritizing and overcoming challenges within cannabinoidderived drug development.
10:15 am Morning Break & Networking
Synopsis
Grab a coffee and buckle up for the next set of morning presentations. This networking session provides a unique offering of group activities to stimulate creativity, foster productivity and enable discussions amongst cannabinoid experts.
11:00 am Session Reserved for Brains Bio
DMPK: Balancing Potency, Metabolism, Efficacy & Dosage to Achieve Patient Safe & Compliant Cannabinoid Drugs
11:30 am Identification of Drug-Induced Liver Injury (DILI) Positive Cannabinoid Molecules
12:00 pm Challenges in Cannabinoid-based Formulations from Development to Clinical Translation
Synopsis
- Understand factors controlling cannabinoid absorption
- Strategies to delivery cannabinoids for specific conditions
- Stability and ingredients compatibility with cannabinoids
- Scale up to manufacture
12:30 pm Lunch & Networking
12:45 pm Virtual presentation hosted during lunch: Chemical Probes & Their Relevance for Drug Discovery Programs Targeting the Endocannabinoid System
Synopsis
- Chemical probes are of utmost importance for bringing drugs from the laboratory through the clinic and ultimately to the market
- Chemical probes support and affect all research and discovery phases
- Examples of probes targeting the cannabinoid receptor type-2 (CB2R) and monoacylglycerol lipase (MAGL) will be highlighted
1:30 pm Roundtable: DMPK, Dosage & Translation: Cannabinoid Molecule Modifications to Achieve in Human Efficacy
Synopsis
Despite significant preclinical potency, cannabinoid molecules exhibit fast drug metabolism and clearance in humans. Join these roundtables to discuss engineering molecules to slow drug metabolism, selecting the right preclinical model, and translationally representative dosage to maintain efficacy levels, to meaningfully progress towards patient compliant oral, once a day dosage regime.
- Selecting the Right Model to Overcome Low Bioavailability
- Designing Preclinical Investigations with Translatable Dosage & Delivery Mechanisms
- Engineering Molecules to Slow Drug Metabolism
2:30 pm Session Reserved for Kare Chemical Technologies
3:00 pm Afternoon Break & Poster Session
Synopsis
Submit, present and review data from across the CBD therapeutic field to get up to speed with pipeline progress beyond the presentations.
Evaluating Polypharmacy: Applications & Interactions of CBD to Disease States & Outcomes
4:00 pm Scientific Rationale on the Combination of CBD & Statins
Synopsis
- Discussing the synergy between CBD and Statins to prove the benefit and practicalities of how CBD associates with Statins
- Detailing avoidance of mitochondrial oxidative stress, anti-inflammatory, and metabolic competitive inhibition through CBD with Statins
4:30 pm Evidence to Support CBD in Diseases of High Mortality: Rationale for Polypharmacy
Synopsis
- In depth discussion of late-breaking data comparing CBD isolate to cannflavins and cannabinoids used in combination in the Tau model of neurodegenerative disease
- Rationale and evidence for the long-term use of cannabinoids in diseases with high mortality
- Analyzing the nuance of cannabinoid rational polypharmacy, "entourage vs non-tourage"